Should We Account Valproate Therapeutic Failure Only to Drug Potency If We Still Cannot Measure Liquid Medications Properly?

Keywords: valproate; medication administration; therapeutic failure EN valproate medication administration therapeutic failure 620 621 2 04/25/23 20230501 NES 230501 Sodium valproate is an anticonvulsant medication available as brand-name/generic tablets, capsules, and liquid (syrup). Individual doses were evaluated by high-performance liquid chromatography for valproic acid content (n = 30).[3] It is important to highlight that valproic acid content in the syrup was 97%, within acceptable pharmacopeial limits (90%-110% of the labeled amount of valproic acid).[3] The results showed that mean valproic acid content in individual doses was 81.8% for 2.5 mL/125 mg (RSD = 17.2%, n = 10), 88.3% for 5 mL/250 mg (RSD = 9.6%, n = 10), and 93.1% for 7.5 mL/375 mg of valproate (RSD = 9%, n = 10) (Figure 1). [Extracted from the article]